AI Verdict
IPAR has stronger fundamentals based on our AI analysis.
IPAR vs IONS Fundamental Comparison
| Metric | IPAR | IONS |
|---|---|---|
| Revenue | $1.5B | $203.3M |
| Net Income | $168.4M | $-381.4M |
| Net Margin | 11.3% | -187.6% |
| ROE | 19.1% | -78.0% |
| ROA | 10.6% | -10.8% |
| Current Ratio | 2.99x | 3.83x |
| Debt/Equity | 0.20x | 3.71x |
| EPS | $5.24 | $-2.38 |
Green = Better metric | Red = Weaker metric
You Might Also Compare
IPAR vs IONS: Frequently Asked Questions
Is IPAR or IONS a better buy in 2026?
Based on dual AI fundamental analysis (Claude and ChatGPT), IPAR has stronger fundamentals. IPAR is rated BUY (78% confidence) while IONS is rated SELL (85% confidence). This is not investment advice.
How does IPAR compare to IONS fundamentally?
INTERPARFUMS INC has ROE of 19.1% vs IONIS PHARMACEUTICALS INC's -78.0%. Net margins are 11.3% vs -187.6% respectively.
Which stock pays higher dividends, IPAR or IONS?
IPAR has a dividend yield of N/A or no dividend while IONS has N/A or no dividend. Check individual stock pages for detailed dividend history and payout ratios.
Should I invest in IPAR or IONS for long term?
For long-term investing, consider that IPAR has BUY rating with 78% confidence, while IONS has SELL rating with 85% confidence. Higher confidence indicates more consistent fundamentals from SEC filings. This is not investment advice - always do your own research.
What do the AI models say about IPAR vs IONS?
Our dual AI system (Claude by Anthropic and ChatGPT by OpenAI) analyzes SEC 10-K and 10-Q filings independently. For IPAR vs IONS, the AI consensus favors IPAR based on fundamental metrics including revenue growth, profitability, ROE, and balance sheet strength.